Blood flow failure as a major determinant in the antitumor action of flavone acetic acid - PubMed (original) (raw)
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid
L J Zwi et al. J Natl Cancer Inst. 1989.
Abstract
Some investigators have suggested that the marked activity of flavone acetic acid (FAA) against advanced solid tumors in mice results from an indirect effect. This study indicates that the critical effect of FAA is irreversible inhibition of tumor blood flow. Perfusion of sc Colon 38 tumors, assessed with H33342 as a fluorescent stain for functional blood vessels, was reduced to 50% of controls within 3 hours of an ip injection of 1.2 mmol of FAA/kg and was completely inhibited by 24 hours. A double-label fluorescence technique demonstrated a significant decrease in blood flow in both sc Colon 38 and im EMT-6/Ak tumors as early as 15 minutes after iv treatment with 1.2 mmol of FAA/kg, with progressively enlarging zones of perfusion failure. The rate of cell death in totally ischemic EMT-6 tumors was shown to be sufficiently rapid to represent a major component of the observed antitumor effect of FAA if the flavonoid acts via inhibition of blood flow. Further, avascular EMT-6/Ak multicellular spheroids growing in the mouse peritoneum are relatively resistant to killing by FAA administered iv or ip, despite extensive infiltration with host immune cells. These results indicate that inhibition of tumor blood flow by FAA is a necessary component of its antitumor activity against solid tumors.
Similar articles
- Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.
Bibby MC, Double JA, Loadman PM, Duke CV. Bibby MC, et al. J Natl Cancer Inst. 1989 Feb 1;81(3):216-20. doi: 10.1093/jnci/81.3.216. J Natl Cancer Inst. 1989. PMID: 2911084 - The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels.
Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Zwi LJ, et al. Br J Cancer. 1990 Aug;62(2):231-7. doi: 10.1038/bjc.1990.266. Br J Cancer. 1990. PMID: 2386739 Free PMC article. - Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect.
Finlay GJ, Smith GP, Fray LM, Baguley BC. Finlay GJ, et al. J Natl Cancer Inst. 1988 Apr 20;80(4):241-5. doi: 10.1093/jnci/80.4.241. J Natl Cancer Inst. 1988. PMID: 3351960 - Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, et al. O'Dwyer PJ, et al. Cancer Chemother Pharmacol. 1987;19(1):6-10. doi: 10.1007/BF00296246. Cancer Chemother Pharmacol. 1987. PMID: 3545524 Review. - Flavone acetic acid--from laboratory to clinic and back.
Bibby MC, Double JA. Bibby MC, et al. Anticancer Drugs. 1993 Feb;4(1):3-17. doi: 10.1097/00001813-199302000-00001. Anticancer Drugs. 1993. PMID: 8457711 Review.
Cited by
- Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.
Pham MH, Rhinn H, Auzeil N, Regazzetti A, Harami DE, Scherman D, Chabot GG. Pham MH, et al. Drug Metab Lett. 2011 Apr;5(2):73-84. doi: 10.2174/187231211795305221. Drug Metab Lett. 2011. PMID: 21457135 Free PMC article. - Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Baguley BC, Siemann DW. Baguley BC, et al. Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Expert Opin Investig Drugs. 2010. PMID: 20964495 Free PMC article. Review. - Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.
Brauer R, Wang LC, Woon ST, Bridewell DJ, Henare K, Malinger D, Palmer BD, Vogel SN, Kieda C, Tijono SM, Ching LM. Brauer R, et al. Neoplasia. 2010 Sep;12(9):755-65. doi: 10.1593/neo.10636. Neoplasia. 2010. PMID: 20824052 Free PMC article. - Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
Ching LM, Zwain S, Baguley BC. Ching LM, et al. Br J Cancer. 2004 Feb 23;90(4):906-10. doi: 10.1038/sj.bjc.6601606. Br J Cancer. 2004. PMID: 14970872 Free PMC article. - Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.
Newell DR, Searle KM, Westwood NB, Burtles SS; Cancer Research UK Phase I/II Clinical Trials Committee. Newell DR, et al. Br J Cancer. 2003 Aug 4;89(3):437-54. doi: 10.1038/sj.bjc.6601106. Br J Cancer. 2003. PMID: 12888809 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous